Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

By J. Dungan. 2011

836 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/36aa07c2fe5ca37fb8d96c6242fa42144d9580e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Roman Yelensky

In Molecular Biology

1. Ingrid A. Mayer
2. Roman Yelensky

Citations in the corpus

• Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. (2012, neutral): “The efficiency of PARP inhibitors on BRCA1/2 mutated breast cancers (52, 53) and the correlation of response to platinum salts with BRCA1”
• Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer. Shifting the Paradigm (2011, neutral): “It is therefore likely that PARP inhibitors will be effective in treating sporadic and hereditary ovarian type II carcinomas as a monotherapy or in combination with other cytotoxic reagents (92-95).”
• Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017, background): “sensitivity to rucaparib and other PARP inhibitors in patients with other cancer types, including nonserous ovarian, gastric, pancreatic, prostate, or breast cancers.(9,22,39-41)”
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “PARP inhibition In the presence of tumor defects in homologous recombination DNA repair, inhibition of the PARP enzyme system may result in ‘synthetic lethality’ and increased cell kill [25].”
• Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation (2014, background): “Clinical trials to date have demonstrated tumor responses and/or progression-free survival (PFS) benefit with the orally active PARP inhibitor olaparib as well as other PARP inhibitors in breast and ovarian cancers associated with germline BRCA1/2 mutations.(4-8) The underlying biology suggests that”
• NEW STRATEGIES FOR TRIPLE NEGATIVE BREAST CANCER – DECIPHERING THE HETEROGENEITY (2014, background): “Overall responses ranged from22%(100mg twice daily) to 41% (400mg twice daily) with minimal toxicity (25).”